Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hagerty

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Hepatology (Baltimore, Md.)|April 30, 2019
ReplyDavid Hagerty, Guadalupe Garcia-Tsao, Jaime Bosch
Annals of the Rheumatic Diseases|May 5, 2010
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexateStanley B Cohen, Edward Keystone, Mark C Genovese, et al.
The New England Journal of Medicine|August 27, 2005
Costimulation blockade with belatacept in renal transplantationFlavio Vincenti, Christian Larsen, Antoine Durrbach, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2004
Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survivalAndrew B Adams, Nozomu Shirasugi, Thomas R Jones, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 15, 2005
Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive propertiesChristian P Larsen, Thomas C Pearson, Andrew B Adams, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Hepatology (Baltimore, Md.)|April 30, 2019
ReplyDavid Hagerty, Guadalupe Garcia-Tsao, Jaime Bosch
Annals of the Rheumatic Diseases|May 5, 2010
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexateStanley B Cohen, Edward Keystone, Mark C Genovese, et al.
The New England Journal of Medicine|August 27, 2005
Costimulation blockade with belatacept in renal transplantationFlavio Vincenti, Christian Larsen, Antoine Durrbach, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2004
Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survivalAndrew B Adams, Nozomu Shirasugi, Thomas R Jones, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 15, 2005
Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive propertiesChristian P Larsen, Thomas C Pearson, Andrew B Adams, et al.
Pageof 1